Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. cardapcells

CardAPcells

Cell therapy for patients with chronic heart failure with proprietary cardiac-derived cells (CardAP cells) – “From the Heart to the Heart”

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 CardAPcells project word cloud

Explore the words cloud of the CardAPcells project. It provides you a very rough idea of what is the project "CardAPcells" about.

cell    manufacturing    morbidity    therapeutic    clinical    trial    cardiac    safety    except    cells    competitors    22    mortality    solution    mio    people    financial    progressive    projected    facilities    hearts    completely    suffering    medicine    specialized    license    exclusive    off    perform    stem    calculations    fulfil    heart    45    acquired    introduction    hospital    advantages    finalised    die    usually    threatening    suffer    business    140    therapies    equity    criteria    rare    stress    market    donor    commercial    life    worldwide    curative    fulfilment    bridge    severe    germany    models    stromal    exemption    transferred    cardiomyopathy    cure    atmp    patients    multicenter    chronic    atmps    area    limited    approval    cardap    preliminary    eacute    artificial    preparations    achievements    preparation    efficacy    spin    disease    regulatory    gmp    financing    insufficiency    university    regulation    cellserve    therapy    plan    charit   

Project "CardAPcells" data sheet

The following table provides information about the project.

Coordinator		 CELLSERVE GMBH 

Organization address
address: CHARITEPLATZ 1
city: BERLIN
postcode: 10117
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.cellserve.de/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-07-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLSERVE GMBH DE (BERLIN) coordinator 50˙000.00

Map

 Project objective

Chronic heart failure is a life-threatening disease usually without cure and a leading cause of morbidity and mortality. In Germany 45 000 patients (projected to EU: about 140 000) die every year from progressive chronic cardiac insufficiency. There is no curative therapeutic solution, except very rare donor hearts and artificial hearts as bridge devices. Researchers at the Charité - University Medicine, have identified unique cardiac-specific stromal cells (CardAP cells) with strong efficacy in cardiac stress models. CardAP cells are specialized heart-derived cells with key advantages in safety and efficacy. CardAP cells fulfil all criteria for cardiac cell therapy and cell product manufacturing has been transferred to GMP facilities. CellServe, a Charité spin off, will develop the CardAP cells for therapy of patients suffering from severe life-threatening cardiomyopathy. CellServe has acquired an exclusive license of this technology and will perform a clinical phase I/II study for patients with chronic cardiomyopathy. The technology of CellServe is completely distinct from all competitors, using specialized stromal heart cells and not stem cells.

CellServe has an experienced management in cell-based therapies area to develop and market ATMP products. It will apply for a so-called hospital exemption regulation, a limited preliminary approval, for early market introduction directly after the clinical study. Commercial potential: Worldwide 22 Mio people suffer from chronic cardiac insufficiency. 
 In Phase 1 a business plan for the CardAP cell product will be generated including financial calculations and the preparations for the clinical study will be finalised.
 Achievements Phase 2:
• Phase I/II clinical trial
• Approval for Hospital Exemption for ATMPs
• Preparation of a multicenter clinical trial
• Fulfilment of all regulatory requirements to perform a phase III clinical study
• Equity financing

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDAPCELLS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDAPCELLS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More